Arbutus Biopharma Corporation ABUS Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$33.5M+52.1% | -$69.92M+4.0% | -$72.85M-4.9% | -$69.46M+8.9% | ||
| $363K-73.7% | $1.38M-1.7% | $1.4M-1.6% | $1.43M-18.6% | ||
| $6.95M-22.6% | $8.99M-3.4% | $9.3M+29.5% | $7.18M+11.8% | ||
| -$1.5M-338% | $633K— | —— | —— | ||
| —— | -$2.73M— | —— | $5.42M+184% | ||
| -$1.7M+26.1% | -$2.3M— | —— | -$2.43M— | ||
| -$557K-29.5% | -$430K+3.2% | -$444K-9.6% | -$405K-8.3% | ||
| —— | -$1.36M+87.3% | -$10.66M— | —— | ||
| -$1.83M-170% | $2.63M+3,704% | $69K-96.9% | $2.23M+19.3% | ||
| —— | —— | —— | —— | ||
| -$39.64M+38.9% | -$64.85M+24.5% | -$85.94M-143% | -$35.36M+47.6% | ||
| $140.06M-1.0% | $141.51M+75.8% | $80.51M-38.3% | $130.43M+58.6% | ||
| $155.28M-5.7% | $164.64M+24.5% | $132.27M+136% | $56M-20.4% | ||
| —— | —— | $50.77M— | —— | ||
| $5.54M-25.9% | $7.48M— | —— | $122K-99.9% | ||
| $5.72M-89.0% | $52M+69.7% | $30.65M-3.7% | $31.81M-76.8% | ||
| —— | —— | $26K+218% | -$22K-540% | ||
| -$18.32M— | —— | —— | -$85.28M-250% | ||
| $2.35M-25.1% | $3.14M+42.8% | $2.2M+3,967% | $54K+105% | ||
| -$1.83M-170% | $2.63M+3,704% | $69K-96.9% | $2.23M+19.3% | ||
| —— | —— | —— | —— | ||
| —— | -$1.36M+87.3% | -$10.66M— | —— | ||
| -$1.7M+26.1% | -$2.3M— | —— | -$2.43M— | ||
| $95K-25.2% | $127K-72.1% | $455K-73.6% | $1.72M-39.6% | ||
| $1.48M-34.2% | $2.25M-41.8% | $3.87M-49.5% | $7.65M+25.3% | ||
| —— | $167K— | —— | —— | ||
| $155.28M-5.7% | $164.64M+24.5% | $132.27M+136% | $56M-20.4% | ||
| —— | —— | —— | —— | ||
| -$39.64M+39.1% | -$65.03M+25.2% | -$86.94M-142% | -$35.87M+47.5% | ||
| -$39.64M+39.1% | -$65.03M+25.2% | -$86.94M-142% | -$35.87M+47.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Arbutus Biopharma Corporation generate?
- Arbutus Biopharma Corporation (ABUS) generated -$34.4M in operating cash flow over the trailing twelve months.
- Where does Arbutus Biopharma Corporation's cash flow data come from?
- Every line is extracted from Arbutus Biopharma Corporation's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
